TIDMMEDG TIDMMEDU
RNS Number : 9526A
Medgenics Inc
05 April 2012
Press Release 5 April 2012
Medgenics, Inc.
("Medgenics" or the "Company")
Medgenics Announces Results of 2012 Annual Meeting of
Stockholders
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own
tissue, today announces that all resolutions proposed at the
Company's Annual Meeting of Stockholders held yesterday were duly
passed.
Each of the current directors of the Company, Dr. Eugene A.
Bauer, Dr. Andrew L. Pearlman, Mr. Joel S. Kanter, Mr. Gary A.
Brukardt, Dr. Stephen D. McMurray, Mr. Isaac Blech and Dr. Alastair
Clemow, was re-elected to the Board of Directors to serve until the
next Annual Meeting of Stockholders and until their successor is
duly elected and qualified.
Stockholders also approved the amendment and restatement of the
Company's Stock Incentive Plan, increasing the number of shares
authorized to be issued under the plan and making certain other
changes to the plan, and ratified the appointment of Kost Forer
Gabbay & Kasierer, a member of Ernst & Young Global, to
serve as the Company's independent registered public accounting
firm for the year ended December 31, 2012.
Final voting tallies are subject to certification by the
Company's inspector of elections, and will be included in the
Company's report to be filed with the Securities and Exchange
Commission later this week.
About Medgenics
Medgenics is developing and commercializing a proprietary
tissue-based platform technology for the sustained production and
delivery of therapeutic proteins using the patient's own skin
biopsy for the treatment of a range of chronic diseases including
anemia, hepatitis C and hemophilia. Medgenics believes this
approach has multiple benefits compared with current treatments,
replacing their regular and costly injections of therapeutic
proteins.
Medgenics has three long-acting protein therapy products in
development based on this technology:
-- EPODURE (now completing a Phase I/II dose-ranging trial) to
produce and deliver erythropoietin for many months from a single
administration, has demonstrated elevation and stabilization of
hemoglobin levels in anemic patients for six to more than 36
months;
-- INFRADURE(TM) (planning to commence a Phase I/II trial in
Israel in 1H12 in hepatitis C) to produce a sustained therapeutic
dose of interferon-alpha for use in the treatment of hepatitis;
-- HEMODURE(TM) is a sustained Factor VIII therapy for the
prophylactic treatment of hemophilia, now in development.
Medgenics is focusing on the development and manufacturing of
its innovative Biopumps(TM) and aims to bring them to market via
strategic partnerships with major pharmaceutical and/or medical
device companies.
In addition to treatments for anemia, hepatitis and hemophilia,
Medgenics plans to develop and/or out-license a pipeline of future
Biopump products targeting the large and rapidly growing global
protein therapy market, which is forecast to reach $132 billion in
2013. Other potential applications for Biopumps include multiple
sclerosis, arthritis, pediatric growth hormone deficiency, obesity
and diabetes.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900
Dr. Andrew L. Pearlman
andrew.pearlman@medgenics.com
LHA Phone: 212-838-3777
Anne Marie Fields
afields@lhai.com
@LHA_IR_PR
Abchurch Communications Phone: +44 207 398 7719
Adam Michael
Joanne Shears
Jamie Hooper
jamie.hooper@abchurch-group.com
Religare Capital Markets UK Ltd. Phone: +44 207 444 0800
(NOMAD)
David Porter
Richard Thompson
SVS Securities plc (Joint Broker) Phone: +44 207 638 5600
Alex Mattey
Ian Callaway
Nomura Code Securities (Joint Broker) Phone: +44 207 776 1219
Jonathan Senior
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGBSGDSRGGBGDU
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Oct 2023 to Oct 2024